La profilaxis con aerosol nasal de interferón-α reduce el COVID-19 en pacientes con cáncer: un ensayo aleatorizado, doble ciego y controlado con placebo
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Ver abstracta en PubMed
Resumen
Este resumen es generado por máquina.Un aerosol nasal diario de interferón alfa (IFN-α) redujo significativamente la incidencia de COVID-19 en pacientes adultos con cáncer. Esta profilaxis fue segura y bien tolerada, ofreciendo una nueva estrategia potencial para la prevención de infecciones en esta población vulnerable.
Área De La Ciencia
- Enfermedades infecciosas
- En el campo de la oncología
- Virología
Sus Antecedentes
- Los pacientes adultos con cáncer tienen un mayor riesgo de contraer COVID-19 grave y otras infecciones virales respiratorias.
- El interferón alfa (IFN-α) tiene propiedades antivirales conocidas.
- La evaluación del IFN-α nasal profiláctico es crucial para proteger a las personas inmunocomprometidas.
Objetivo Del Estudio
- Para determinar si el aerosol nasal diario de interferón alfa (IFN-α) reduce la incidencia de COVID-19 en pacientes adultos con cáncer.
- Evaluar la eficacia del aerosol nasal IFN-α contra otras infecciones virales respiratorias adquiridas en la comunidad.
- Evaluar la seguridad y tolerabilidad de la profilaxis nasal con IFN-α.
Principales Métodos
- Un ensayo multicéntrico, aleatorizado, doble ciego y controlado con placebo.
- Los participantes recibieron diariamente 40.000 UI de IFN-α en aerosol nasal o placebo.
- La PCR y las pruebas rápidas de antígeno se utilizaron para la detección viral en individuos sintomáticos.
Principales Resultados
- El aerosol nasal IFN-α redujo la incidencia de COVID-19 en un 40% (RR: .60; 95% CrI: .33-.97).
- No se observaron diferencias significativas en las tasas de otras infecciones virales respiratorias entre los grupos.
- Los análisis de subgrupos mostraron un mayor beneficio en pacientes más jóvenes (< 65 años), mujeres y vacunados.
Conclusiones
- La profilaxis nasal con interferón alfa (IFN-α) redujo efectivamente la incidencia de COVID-19 en pacientes adultos con cáncer.
- El tratamiento fue seguro y bien tolerado, sin aumento del riesgo de resultados graves.
- El aerosol nasal IFN-α representa una medida preventiva prometedora para las poblaciones de alto riesgo de cáncer.
Contact us Si estos videos no son relevantes.
Contact us Si estos videos no son relevantes.
Videos de Conceptos Relacionados
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...